 LEXINGTON, Mass.--BUSINESS WIRE--Aldeyra Therapeutics, Inc. Nasdaq: ALDX Aldeyra today announced confirmation of SARS-CoV-2 antiviral activity of ADX-1612, in addition to novel anti-inflammatory activity in SARS-CoV-2-infected primary human cells in preclinical studies. The results are derived from an international collaboration with the Max Delbrück Center for Molecular Medicine in the Helmholtz Association MDC in Berlin, Germany, which plans additional studies with colleagues at the C 